Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8840896 Anti-HER2 antibody variants

Patent 8840896 was granted and assigned to Genentech on September, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Genentech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8840896

Patent Inventor Names

Henry B. Lowman0

Paul J. Carter0

Resi B. Gerstner0

Date of Patent

September 23, 2014

Patent Application Number

12966834

Date Filed

December 13, 2010

Patent Citations Received

‌

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 11654105 Subcutaneous HER2 antibody formulations

‌

US Patent 11655305 Treatment of metastatic breast cancer

‌

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

Patent Primary Examiner

‌

Lynn Bristol

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8840896 Anti-HER2 antibody variants

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API